Cardioprotective Properties Of Xenon
A. I. Shpichko,
O. A. Grebenchikov,
I. V. Molchanov,
A. K. Shabanov,
N. P. Shpichko,
K. K. Kadantseva https://doi.org/10.23934/2223-9022-2020-9-2-264-272
Abstract
Abstract The review presents the main aspects of the cardioprotective properties of the xenon inhalation anesthetic. Based on the analysis of publications, the article discusses modern views on the mechanisms of the protective action of xenon, realized using pre- and post-conditioning mechanisms, shows major molecular targets and their effects. The article presents the results of experimental studies in vivo and in vitro, which showed the protective effect of xenon on the myocardium and the results of recent randomized clinical trials. The analysis of studies demonstrates the ability of xenon to increase myocardial resistance to ischemia and reperfusion and opens up good prospects for its use in clinical practice in patients with a high risk of cardiac complications.
About the Authors
A. I. Shpichko
Federal Scientific and Clinical Center for Resuscitation and Rehabilitation
Russian Federation
Russian Federation
Cand. Med. Sci., Senior Researcher at the Laboratory of Organ Protection in Critical Conditions
25, b. 2 Petrovka St., Moscow 107031
O. A. Grebenchikov
Federal Scientific and Clinical Center for Resuscitation and Rehabilitation
Russian Federation
Russian Federation
Dr. Med. Sci., Chief Researcher at the Laboratory of Organ Protection in Critical Conditions
25, b. 2 Petrovka St., Moscow 107031
I. V. Molchanov
Federal Scientific and Clinical Center for Resuscitation and Rehabilitation
Russian Federation
Russian Federation
Doctor of Medical Sciences, Professor, Head of the Research Institute of General Resuscitation
25, b. 2 Petrovka St., Moscow 107031
A. K. Shabanov
Federal Scientific and Clinical Center for Resuscitation and Rehabilitation; N.V. Sklifosovsky Research Institute for Emergency Medicine of the Moscow Health Department
Russian Federation
Russian Federation
Doctor of Medical Sciences, Chief Researcher, Clinical Laboratory of Pathophysiology in Critical Conditions;
Deputy Chief Physician for Anesthesiology and Resuscitation
25, b. 2 Petrovka St., Moscow 107031
3 B. Sukharevskaya Sq., Moscow 129090
N. P. Shpichko
Federal Scientific and Clinical Center for Resuscitation and Rehabilitation
Russian Federation
Russian Federation
Researcher at the Laboratory of Motor Rehabilitation, Restoration of Swallowing and Speech
25, b. 2 Petrovka St., Moscow 107031
K. K. Kadantseva
Federal Scientific and Clinical Center for Resuscitation and Rehabilitation
Russian Federation
Russian Federation
Researcher at the Laboratory of Organ Protection in Critical Conditions
25, b. 2 Petrovka St., Moscow 107031
References
1. The BARI investigators. The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol. 2007;49(15):1600–1606. PMID: 17433949 https://doi.org/10.1016/j.jacc.2006.11.048
2. Al-Hijji M, El Sabbagh A, Holmes DR. Revascularization for Left Main and Multivessel Coronary Artery Disease: Current Status and Future Prospects after the EXCEL and NOBLE Trials. Korean Circ J. 2018;48(6): 447–462. PMID: 29856140 https://doi.org/10.4070/kcj.2018.0078
3. Møller CH, Penninga L, Wetterslev J, Steinbrüchel DA, Gluud C. Offpump versus on-pump coronary artery bypass grafting for ischaemic heart disease. Cochrane Database Syst Rev. 2012;(3):CD007224. PMID: 22419321 https://doi.org/10.1002/14651858.CD007224.pub2
4. Kozlov IA, Ovezov AM, Petrovskaya EL. Perioperative Myocardial Damage and Heart Failure in Noncardiac Surgery. Part 1. Etiopathogenesis and Prognosis of Perioperative Cardiac Complications (Review). General Reanimatology. 2019;15(2):53–78. (In Russ.) https://doi.org/10.15360/1813-9779-2019-2-53-78
5. Devereaux PJ, Goldman L, Cook DJ, Gilbert K, Leslie K, Guyatt GH. Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. CMAJ. 2005;173(6):627–634. PMID: 16157727 https://doi.org/10.1503/cmaj.050011
6. Kristensen SD, Knuuti J, Saraste A, Anker S, Bøtker HE, De Hert S, et al. ESC/ESA Guidelines on non–cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol. 2014;31(10):517–573. PMID: 25127426 https://doi.org/10.1097/EJA.0000000000000150
7. Likhvantsev VV, Skripkin YuV, Grebenchikov OA, Il’in YuV, Shaposhnikov BA, Mironenko AV. Mekhanizmy deystviya i osnovnye effekty galogensoderzhashchikh anestetikov. Vestnik Intensivnoj Terapii. 2013; (3): 44–51. (In Russ.)
8. Moroz VV, Silachev DN, Plotnikov EY, Zorova LD, Pevzner IB, Grebenchikov OA, et al. Mechanisms of Cell Damage and Protection in Ischemia/Reperfusion and Experimental Rationale for the Use of Lithium-Based Preparations in Anesthesiology. General Reanimatology. 2013;9(1):63. (In Russ.) https://doi.org/10.15360/1813-9779-2013-1-63
9. Kersten JR, Schmeling М, Pagel PS, Gross GJ, Warltier DC. Isoflurane mimics ischemic preconditioning via activation of K (ATP) channels. Reduction of myocardial infarct size with acute memory phase. Anesthesiology. 1997;87(2):361–370. PMID: 9286901 https://doi.org/10.1097/00000542-199708000-00024
10. De Hert SG, Turani F, Mathur S, Stowe DF. Cardioprotection with volatile anesthetics: mechanisms and clinical implications. Anesth Analg. 2005;100(6):1584–1593. PMID: 15920178 https://doi.org/10.1213/01.ANE.0000153483.61170.0C
11. Murry CE, Richard VJ, Jennings RB, Reimer KA. Myocardial protection is lost before contractile function recovers from ischemic preconditioning. Am J Physiol. 1991;260(3,Pt2):796–805. PMID: 2000974 https://doi.org/10.1152/ajpheart.1991.260.3.H796
12. Roehl AB, Funcke S, Becker MM, Goetzenich A, Bleilevens C, Rossaint R, et al. Xenon and isoflurane reduce left ventricular remodeling after myocardial infarction in the rat. Anesthesiology. 2013;118(6):1385–1394. PMID: 23364599 https://doi.org/10.1097/ALN.0b013e31828744c0
13. Schwiebert C, Huhn R, Heinen A, Weber NC, Hollmann MW, Schlack W, et al. Postconditioning by xenon and hypothermia in the rat heart in vivo. Eur J Anaesthesiol. 2010;27(8):734–739. PMID: 20051868 https://doi.org/10.1097/EJA.0b013e328335fc4c
14. Li Q, Lian C, Zhou R, Li T, Xiang X, Liu B. Pretreatment with xenon protected immature rabbit heart from ischaemia/reperfusion injury by opening of the mitoKATP channel. Heart Lung Circ. 2013;22(4):276–283. PMID: 23261327 https://doi.org/10.1016/j.hlc.2012.10.016
15. Mio Y, Shim YH, Richards E, Bosnjak ZJ, Pagel PS, Bienengraeber M. Xenon preconditioning: the role of prosurvival signaling, mitochondrial permeability transition and bioenergetics in rats. Anesth Analg. 2009;108(3):858–866. PMID: 19224794 https://doi.org/10.1213/ane.0b013e318192a520
16. Hausenloy DJ, Lecour S, Yellon DM. Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin. Antioxid Redox Signal. 2011;14(5):893–907. PMID: 20615076 https://doi.org/10.1089/ars.2010.3360
17. Weber NC, Toma O, Wolter JI, Obal D, Müllenheim J, Preckel B, et al. The noble gas xenon induces pharmacological preconditioning in the rat heart in vivo via induction of PKC-epsilon and p38 MAPK. Br J Pharmacol. 2005;144(1):123–132. PMID: 15644876 https://doi.org/10.1038/sj.bjp.0706063
18. Weber NC, Toma O, Wolter JI, Wirthle NM, Schlack W, Preckel B. Mechanisms of xenon- and isoflurane-induced preconditioning - a potential link to the cytoskeleton via the MAPKAPK-2/HSP27 pathway. Br J Pharmacol. 2005;146(3):445–455. PMID: 16086037 https://doi.org/10.1038/sj.bjp.0706324
19. Liu W, Liu Y, Chen H, Liu K, Tao H, Sun X. Xenon preconditioning: molecular mechanisms and biological effects. Med Gas Res. 2013;3(1):3. PMID: 23305274 https://doi.org/10.1186/2045-9912-3-3
20. Simkhovich BZ, Przyklenk K, Kloner RA. Role of protein kinase C in ischemic “conditioning”: from first evidence to current perspectives. J Cardiovasc Pharmacol Ther. 2013;18(6):525–532. PMID: 23872508 https://doi.org/10.1177/1074248413494814
21. Weber NC, Toma O, Damla H, Wolter JI, Schlack W, Preckel B. Upstream signaling of protein kinase C-epsilon in xenon-induced pharmacological preconditioning. Implication of mitochondrial adenosine triphosphate dependent potassium channels and phosphatidylinositol-dependent kinase-1. Eur J Pharmacol. 2006;539(1–2):1–9. PMID: 16716295 https://doi.org/10.1016/j.ejphar.2006.03.054
22. Weber NC, Stursberg J, Wirthle NM, Toma O, Schlack W, Preckel B. Xenon preconditioning differently regulates p44/42 MAPK (ERK 1/2) and p46/54 MAPK (JNK 1/2 and 3) in vivo. Br J Anaesth. 2006;97(3):298–306. PMID: 16793779 https://doi.org/10.1093/bja/ael153
23. Weber NC, Frässdorf J, Ratajczak C, Grueber Y, Schlack W, Hollmann MW, et al. Xenon induces late cardiac preconditioning in vivo: a role for cyclooxygenase 2? Anesth Analg. 2008;107(6):1807–1813. PMID: 19020121 https://doi.org/10.1213/ane.Ob013e31818874bf
24. Weber NC, Kandler J, Schlack W, Grueber Y, Frädorf J, Preckel B. Intermitted pharmacologic pretreatment by xenon, isoflurane, nitrous oxide, and the opioid morphine prevents tumor necrosis factor alphainduced adhesion molecule expression in human umbilical vein endothelial cells. Anesthesiology. 2008;108(2):199–207. PMID: 18212564 https://doi.org/10.1097/01.anes.0000299441.32091.ed
25. Rossaint R, Reyle-Hahn M, Schulte Am Esch J, Scholz J, Scherpereel P, Vallet B, et al. Multicenter randomized comparison of the efficacy and safety of xenon and isoflurane in patients undergoing elective surgery. Anesthesiology. 2003;98(1):6–13. PMID: 12502972 https://doi.org/10.1097/00000542-200301000-00005
26. Wappler F, Rossaint R, Baumert J, Scholz J, Tonner PH, van Aken H, et al. Multicenter randomized comparison of xenon and isoflurane on left ventricular function in patients undergoing elective surgery. Anaesthesiology. 2007;106(3):463–471. PMID: 17325504 https://doi.org/10.1097/00000542-200703000-00010
27. Baumert JH, Roehl AB, Funcke S, Hein M. Xenon protects left ventricular diastolic function during acute ischemia, less than ischemic preconditioning. Med Gas Res. 2016;6(3):130–137. PMID: 27867480 https://doi.org/10.4103/2045-9912.191358
28. Preckel B, Müllenheim J, Moloschavij A, Thämer V, Schlack W. Xenon administration during early reperfusion reduces infarct size after regional ischemia in the rabbit heart in vivo. Anesth Analg. 2000;91(6):1327–1332. PMID: 11093973 https://doi.org/10.1097/00000539-200012000-00003
29. Coburn M, Kunitz O, Baumert JH, Hecker K, Haaf S, Zühlsdorff A, et al. Randomized controlled trial of the haemodynamic and recovery effects of xenon or propofol anaesthesia. Br J Anaesth. 2005;94(2):198–202. PMID: 15531620 https://doi.org/10.1093/bja/aei023
30. Baumert JH, Hein M, Hecker KE, Satlow S, Neef P, Rossaint R. Xenon or propofol anaesthesia for patients at cardiovascular risk in non-cardiac surgery. Br J Anaesth. 2008;100(5):605–611. PMID: 18344556 https://doi.org/10.1093/bja/aen050
31. Law LS, Lo EA, Gan TJ. Xenon anesthesia: A systematic review and metaanalysis of randomized controlled trials. Anesth Analg. 2016;122(3):678–697. PMID: 26273750 https://doi.org/10.1213/ANE.0000000000000914
32. Xia Y, Fang H, Xu J, Jia C, Tao G, Yu B. Clinical efficacy of xenon versus propofol: A systematic review and meta-analysis. Medicine (Baltimore). 2018;97(20):e10758. PMID: 29768360 https://doi.org/10.1097/MD.0000000000010758
33. Dingley J, King R, Hughes L, Terblanche C, Mahon S, Hepp M, et al. Exploration of xenon as a potential cardiostable sedative: a comparison with propofol after cardiac surgery. Anaesthesia. 2001;56(9):829–835. PMID: 11531666 https://doi.org/10.1046/j.1365-2044.2001.02139.x
34. Stoppe C, Fahlenkamp AV, Rex S, Veeck NC, Gozdowsky SC, Schälte G, et al. Feasibility and safety of xenon compared with sevoflurane anaesthesia in coronary surgical patients: A randomized controlled pilot study. Br J Anaesth. 2013;111(3):406–416. PMID: 23578862 https://doi.org/10.1093/bja/aet072
35. Lockwood GG, Franks NP, Downie NA, Taylor KM, Maze M. Feasibility and safety of delivering xenon to patients undergoing coronary artery bypass graft surgery while on cardiopulmonary bypass: Phase I study. Anesthesiology. 2006;104(3):458–465. PMID: 16508392 https://doi.org/10.1097/00000542-200603000-00012
36. Al Tmimi L, Van Hemelrijck J, Van de Velde M, Sergeant P, Meyns B, Missant C, et al. Xenon anaesthesia for patients undergoing offpump coronary artery bypass graft surgery: A prospective randomized controlled pilot trial. Br J Anaesth. 2015;115(4):550–559. PMID: 26385664 https://doi.org/10.1093/bja/aev303
37. Mokhtar AT, Begum J, Buth KJ, Legare JF. Cardiac troponin T is an important predictor of mortality after cardiac surgery. J Crit Care. 2017;38:41–46. PMID: 27837691 https://doi.org/10.1016/j.jcrc.2016.10.011
38. Hofland J, Ouattara A, Fellahi J-L, Gruenewald M, Hazebroucq J, Ecoffey C, et. аl. Effect of Xenon Anesthesia Compared to Sevoflurane and Total Intravenous Anesthesia for Coronary Artery Bypass Graft Surgery on Postoperative Cardiac Troponin Release An International, Multicenter, Phase 3, Single-blinded, Randomized Noninferiority Trial. Anesthesiology. 2017;127(6):918–933. PMID: 28872484 https://doi.org/10.1097/ALN.0000000000001873
39. Arola O, Saraste A, Laitio R, Airaksinen J, Hynninen M, Bäcklund M, et al. Inhaled Xenon Attenuates Myocardial Damage in Comatose Survivors of Out-of-Hospital Cardiac Arrest: The Xe-Hypotheca Trial. J Am Coll Cardiol. 2017;70(21):2652–2660. PMID: 29169472 https://doi.org/0.1016/j.jacc.2017.09.1088/2017
40. Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002;346(8):549–556. PMID: 11856793 https://doi.org/10.1056/NEJMoa012689
41. Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, et al. Targeted temperature management at 33°C versus 36°C after cardiac arrest. N Engl J Med. 2013;369(23):2197–2206. PMID: 24237006 https://doi.org/10.1056/NEJMoa1310519
42. Gräsner JT, Lefering R, Koster RW, Masterson S, Böttiger BW, Herlitz J, et al. EuReCa ONE-27 Nations, ONE Europe, ONE Registry: a prospective one month analysis of out-of-hospital cardiac arrest outcomes in 27 countries in Europe. Resuscitation. 2016;105:88-195. PMID: 27321577 https://doi.org/10.1016/j.resuscitation.2016.06.004
43. Breuer T, Emontzpohl C, Coburn M, Benstoem C, Rossaint R, Marx G, et al. Xenon triggers pro-inflammatory effects and suppresses the anti-inflammatory response compared to sevoflurane in patients undergoing cardiac surgery. Crit Care. 2015;19:365. PMID: 29623938 https://doi.org/10.4103/1673-5374.228757
Review
For citations:
Shpichko A.I., Grebenchikov O.A., Molchanov I.V., Shabanov A.K., Shpichko N.P., Kadantseva K.K. Cardioprotective Properties Of Xenon. Russian Sklifosovsky Journal "Emergency Medical Care". 2020;9(2):264-272. https://doi.org/10.23934/2223-9022-2020-9-2-264-272
Views:
807
Email this article 